Acute Bronchiolitis and Severity Markers: Interest in Protein CC16 (CC16)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02984046|
Recruitment Status : Unknown
Verified December 2016 by University Hospital, Clermont-Ferrand.
Recruitment status was: Recruiting
First Posted : December 6, 2016
Last Update Posted : December 6, 2016
Acute bronchiolitis is a common viral infection in infants mainly due to RSV and rhinovirus.
Biomarkers can be useful for predicting its severity. The serum CC16 is a marker of epithelial aggression. Its rate increase during RSV bronchiolitis in infants less than 7 months. It could be an early predictive biomarker of the severity of acute bronchiolitis, and secondarily for the development of asthma.
Two other markers of airway aggression seem to increase during acute bronchiolitis: serum SP-D protein and serum soluble receptor sRAGE.
|Condition or disease||Intervention/treatment||Phase|
|Acute Bronchiolitis||Drug: Protein CC16||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Acute Bronchiolitis and Severity Markers: Interest in Protein CC16|
|Study Start Date :||November 2015|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||January 2019|
Experimental: acute bronchiolitis
Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system
Drug: Protein CC16
- Serum CC16 rate [ Time Frame: at day 1 ]
- Urinary CC16 rate [ Time Frame: at day 1 ]
- SP-D rates [ Time Frame: at day 1 ]
- sRAGE rates [ Time Frame: at day 1 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02984046
|Contact: Patrick LACARINfirstname.lastname@example.org|
|Clermont-Ferrand, France, 63003|
|Contact: Patrick LACARIN 0473751195 email@example.com|
|Principal Investigator: André LABBE|
|Principal Investigator:||André LABBE||University Hospital, Clermont-Ferrand|